Muriel Busson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muriel Busson has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Corinne Prévostel
IRCM (Montpellier Cancer Research Institute), University of Montpellier, Inserm, ICM (Montpellier Regional Cancer Institute), 34298 Montpellier, CEDEX 5, France
10 shared publications - Gilles Subra
IBMM, University of Montpellier, CNRS, ENSCM, Montpellier, France
10 shared publications Lucile Canterel-Thouennon
10 shared publications- Marc Ychou
Department of Medical oncology, Montpellier Cancer Institute (ICM), Montpellier University , Montpellier 34298 Cedex 5
10 shared publications - Pascal Verdié
Institut des Biomolécules Max Mousseron UMR 5247, Université de Montpellier, ENSCM, Montpellier 34093, France
10 shared publications - Philippe Blache
IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
10 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Crystal violet staining (n = 6) at day 11 post-seeding demonstrates that mutation of the conserved aspartic acid residue into alanine in the S9pep N-terminus only slightly reduces S9pep effect on DLD-1 cell growth compared with wild type S9pep. By contrast, SOX9K205-G225 abolishes the S9pep effect on DLD-1 cell growth.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Crystal violet staining (n = 6) at day 11 post-seeding demonstrates that mutation of the conserved aspartic acid residue into alanine in the S9pep N-terminus only slightly reduces S9pep effect on DLD-1 cell growth compared with wild type S9pep. By contrast, SOX9K205-G225 abolishes the S9pep effect on DLD-1 cell growth.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
SOX-luciferase reporter assay (n = 3) shows SOX activity in DLD-1 cells after induction or not of SOX9 (S9-DLD-1 cells, used here as a positive control) or S9pep (S9pep-DLD-1 cells) by incubation with doxycycline. While SOX activity is, as expected, drastically increased in response to doxycycline-induced SOX9 expression, doxycycline-induced S9pep expression has no significant effect.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
SOX-luciferase reporter assay (n = 3) shows SOX activity in DLD-1 cells after induction or not of SOX9 (S9-DLD-1 cells, used here as a positive control) or S9pep (S9pep-DLD-1 cells) by incubation with doxycycline. While SOX activity is, as expected, drastically increased in response to doxycycline-induced SOX9 expression, doxycycline-induced S9pep expression has no significant effect.